{
    "text": "Therefore, the AKT inhibitor perifosine might potentially overcome the resistance to cisplatin-based chemotherapy in NSCLC patients with low-FHIT tumors, and consequently improve the outcome.", 
    "denotations": [
        {
            "id": "T1", 
            "obj": "AKT", 
            "span": {
                "begin": 15, 
                "end": 18
            }
        }, 
        {
            "id": "T1", 
            "obj": "NSCLC", 
            "span": {
                "begin": 117, 
                "end": 122
            }
        }, 
        {
            "id": "T1", 
            "obj": "FHIT", 
            "span": {
                "begin": 141, 
                "end": 145
            }
        }
    ],
    "relations": [
        {
            "id":"R1",
            "pred":"causes",
            "subj":"T2", 
          "obj":"T1"}
    ]
}